Conclusion:
Nocturnally administered sodium oxybate improved excessive daytime sleepiness and fatigue in PD.
Trial Registration: clinicaltrials.gov Identifier: NCT00641186 Arch Neurol. 2008;65 (10) : [1337] [1338] [1339] [1340] P ARKINSON DISEASE (PD) IS strongly associated with the following 2 broad categories of sleep abnormalities: excessive daytime sleepiness (EDS) and nocturnal sleep dysfunction. Excessive daytime sleepiness has been well demonstrated using the subjective Epworth Sleepiness Scale (ESS) and objective polysomnography (PSG), including multiple sleep latency testing. The consequences of EDS, however, are sometimes difficult to segregate clearly from fatigue, lethargy, and depression, all of which are also common in PD.
Excessive daytime sleepiness in PD has generally been associated with greater age, more advanced disease, and dopaminergic drug use. [1] [2] [3] [4] [5] Therefore, both PD and its treatment can cause EDS. Nocturnal sleep in PD is also markedly abnormal. Documented problems include fragmented sleep with multiple arousals and/or full awakenings associated with rigidity, dystonia, tremor, pain, sialorrhea, and nocturia [6] [7] [8] ; rapid eye movement sleep behavior disorder [9] [10] [11] ; periodic limb movements 12, 13 ; restless legs syndrome 14 ; and sleep apnea. 15 Some of these may precede the motor symptoms of PD by many years. Intrinsic changes in sleep architecture are less marked but include reduced slow-wave sleep (SWS) and reduced sleep spindles. 16, 17 Although it seems intuitive, studies have not confirmed a correlation between nocturnal sleep dysfunction and EDS in PD. 16, 18 Relatively little therapeutic research has addressed these problems. Modafinil [19] [20] [21] has been demonstrated to have some benefit for EDS in patients with PD, al-though the improvement was modest. To our knowledge, no reported therapeutic studies have carefully evaluated a specific treatment for nocturnal sleep problems in the PD population.
Sodium oxybate (Xyrem; Jazz Pharmaceuticals, Inc) is a unique compound approved by the US Food and Drug Administration for the treatment of cataplexy and EDS in patients with narcolepsy. 22, 23 Owing to the potential for abuse, especially when mixed with alcohol (this is a salt of ␥-hydroxybutyrate, the "date rape drug"), use of sodium oxybate is restricted through a central pharmacy registry. Sodium oxybate is a metabolite of ␥-aminobutyric acid, although it may be an independent endogenous neurotransmitter, with a very short half-life and short clinical effect, usually 2.5 to 4.0 hours. Therefore, 2 doses are used to achieve a typical full night of sleep, one at initiation of sleep and the other 4 hours later. Polysomnographic studies show a consistent increase in SWS in subjects with normal sleep 24 and in those with sleep abnormalities. 25 We evaluated the use of sodium oxybate for EDS in subjects with PD in a multicenter, open-label, PSG study. We enrolled subjects with PD, aged 30 to 75 years, with Hoehn and Yahr stages 1.5 to 4.0 during periods while practically defined off ("off") medication, Mini-Mental State Examination scores of greater than 24, ESS scores of greater than 10, and a patient report of unsatisfactory sleep. This could include any sleep concern, but always resulted in some insomnia. The subjects could not be taking medications with known central nervous system-depressant properties and had been receiving stable PD medications for at least 30 days before and throughout the study. We excluded subjects with serious medical conditions, including renal insufficiency or congestive heart failure, depression (Beck Depression Inventory score, Ͼ16), or known sleep apnea or narcolepsy.
The subjects underwent a screening/acclimation PSG. They were subsequently excluded if they had more than mild sleep apnea (apnea/hypopnea index Ͼ15) and oxygen desaturation levels consistently below 90%. Obstructive apneas were scored as 10 seconds of more than 90% airflow reduction with continued respiratory effort. Obstructive hypopneas were scored as 10-second epochs of more than 30% airflow reduction associated with either a 3% oxygen desaturation or an electroencephalographic arousal.
Within 7 days, the subjects underwent the entry PSG. They returned to the clinic the following morning without taking their usual PD medications (off-medication state) and underwent assessment with the Unified Parkinson Disease Rating Scale (UPDRS). After taking their PD medications, they completed the Fatigue Severity Scale (FSS), Pittsburgh Sleep Quality Inventory (PSQI), the 36-Item Short Form Health Survey quality-of-life assessment, and the ESS (primary efficacy point). The subjects then started sodium oxybate therapy, 4.5 g per night, to be taken in 2 equally divided doses: 2.25 g (4.5 mL) at bedtime, and 2.25 g (4.5 mL) 2.5 to 4.0 hours later. They woke naturally or set an alarm for their second dose. A follow-up telephone call 1 week later reviewed medication adherence and any possible adverse effects. The subjects were examined after 2 weeks of therapy with reevaluations of the ESS score, vital signs, and adverse events. The dose was increased to 6 g per night, to be taken in 2 equally divided doses. After another follow-up telephone call and according to the clinical judgment of site investigators, the dose was increased weekly by 1.5-g increments to a maximum nightly dose of 9.0 g. In the event that adverse effects developed with the higher doses, the dose could be reduced to a tolerated level for the remainder of the trial. The final clinic visit (study day 56) included a final PSG, followed by an off-medication UPDRS evaluation, then a repeated battery of tests after PD medication therapy was restored. The subjects returned all unused drug.
The primary efficacy point was change in the ESS score (daytime sleepiness). Other measures of daytime symptoms (the FSS score) and nocturnal symptoms (the polysomnogram and PSQI) were secondary measures. Statistics included descriptive calculations and paired, 2-tailed t tests. Significance was set at PϽ.05. Study design, data management, database design, statistical analysis, and manuscript drafting were all performed by the primary investigator (W.G.O.), who maintains ownership of the data. The primary investigator received an Investigational New Drug exemption from the US Food and Drug Administration for the study. Unless otherwise specified, data are expressed as mean (SD).
RESULTS
Thirty-eight subjects with PD were enrolled to achieve 30 successful screenings. We excluded 8 subjects at screening secondary to sleep apnea criteria (n=7) and depression (n=1). Three subjects dropped out after randomization for dizziness (n=3) and concurrent depression (n=1); 2 of these dropped out before any follow-up data were collected and were therefore excluded from the efficacy analysis. The 6-week subjective sleep data in the third subject were included as the last observation carried forward.
The mean age of the 30 subjects (of whom 24 were men) was 61.5 (8.7) years, and the duration of PD was 8.6 (5.5) years (range, 1-25 years). The Hoehn and Yahr stages were 2.0 (n=14), 2.5 (n=11), and 3.0 (n=5). Twenty-seven subjects were white, 2 were Hispanic, and 1 was Asian. The mean entry Mini-Mental State Examination score was 29.1 (1.3) (range, 25-30). All subjects were treated with a dopamine agonist without levodopa (n = 8), levodopa without a dopamine agonist (n=3), or levodopa and a dopamine agonist (n=19). Six of the subjects taking levodopa and a dopamine agonist also took a monoamine oxidase type B inhibitor; 10 subjects took a catechol-O-methyltransferase inhibitor; and 11 subjects took amantadine hydrochloride.
The mean final dose of sodium oxybate was 7.8 (1.7) g per night. The final nightly doses were 3.0 g (n=2), 4.5 g (n=1), 6.0 g (n=6), 7.5 g (n=4), and 9.0 g (n=17).
The ESS, PSQI, and FSS scores improved significantly. Changes in the 36-Item Short Form Health Survey score were not significant ( Table 1) .
Slow-wave sleep time increased in 27 subjects, (P=.005) ( Adverse events probably or definitely related to the drug included dizziness (n=3), nocturia/enuresis (n=3), nausea (n=1), daytime sleepiness (n = 1), reduced alertness (n=1), and rebound morning tremor (n =1). One subject reported increased morning tremor. Additional adverse events that were considered not related to the study drug included constipation (n = 1), 1 delusions (n=1), 1 and, in a single subject, bradycardia, anxiety, depression, and edema. Twenty-two of 30 subjects (73%) reported no adverse events.
At the study's conclusion, 18 of 27 subjects (67%) completed application forms for the central distribution pharmacy to continue sodium oxybate therapy.
COMMENT
Overall, nocturnally administered sodium oxybate was well tolerated, increased SWS, and improved subjective nighttime and daytime sleep problems and daytime fatigue in subjects with PD. Improvements in ESS were similar to or better than those found when the drug is used as therapy for narcolepsy. 22, 23 The PD motor features were unchanged.
The mechanism by which sodium oxybate improves EDS is not known. It is known to increase SWS 26 ; however, our study did not show a significant correlation between improved SWS and ESS scores. The SWS change in our study compared only 2 nights and is variable. In addition, our study was not powered in any way to specifically address this question, so we cannot entirely exclude the possibility of SWS variations. Sodium oxybate has also been postulated to improve EDS by decreasing sleep fragmentation in narcolepsy trials 25 ; however, we found improved EDS without reduced awakenings in this PD study. Furthermore, deep brain stimulation of the subthalamic nucleus improves sleep fragmentation associated with nocturnal motor abnormalities in subjects with PD but has not improved EDS in a small number of studied subjects. 27 As an alternative explanation, nocturnal sodium oxybate use may result in the rebound vigilant state observed during the day after nighttime administration. The short half-life of sodium oxybate allows for complete washout by the morning, when increased release of stored dopamine and norepinephrine may occur and contribute to the observed enhanced wakefulness. 28, 29 Dopamine release is actually inhibited while the drug is active, which may account for the nonsignificant increase in periodic limb movements. 30 We did not believe that the slight increase in apnea was clinically meaningful, but this needs to be monitored. There was no evidence of abuse.
This study has all of the shortcomings of any openlabel trial. We intentionally designed broad inclusion criteria and did not exclude subjects with restless legs syndrome or rapid eye movement sleep behavior disorder, neither of which appears to affect EDS in PD.
14 Given the robust efficacy and good tolerability of the study drug and the lack of effective treatment for EDS in patients with PD, we believe that controlled trials using objective measures of daytime sleepiness are justified. Abbreviations: PLMs, periodic limb movements; PSG, polysomnography; REM, rapid eye movement.
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a Calculation of the index is explained in the "Methods" section.
